RETURN TO INDEX  

Pfizer move to Quash Committee Report on Controversial (Nigeria) Drug Test

August 1 2007 at 10:10 PM
admin 


Response to Pfizer DEFENDANTS NAMED in Nigerian Gov's denial of 'withdrawn' lawsuit

http://allafrica.com/stories/200707310024.html

"Nigeria: Pfizer Moves to Quash Committee Report on Controversial Drug Test

Pharmaceutical giant, Pfizer, yesterday began a legal move before the Abuja division of the Federal high court to quash a report by the Investigating Committee on the Clinical Trial of Trovan conducted in Kano in 1996 which indicted it (Pfizer).

The fresh suit seeking for an order of certiorari reviewing the report with a view to quashing it has been assigned to Justice Anwuri Chikere for trial.

The application for certiorari, if successful, is capable of collapsing the multiple criminal and civil actions pending against the pharmaceutical giants. The case briefly came up yesterday before the high court judge who granted Pfizer an extension of time to apply for leave to challenge the report.

The Federal Government, had, last week, charged Pfizer Incorporated and eight others before the Federal high court sitting in Abuja with alleged criminal application of a killer-drug known as "Trovafloxacin," more than a decade ago, on 200 Nigerian children, terminating lives of many of them, with others suffering various permanent disabilities.

The eight others are Pfizer Nigeria, Isa Dutse, Scott Hopkins, Debra Williams, Mike Dunne, Samuel Ohuabunwa, Robert Buhl and William Steere. They are facing a total 23-count charge.

The case though had come up for mention in court but the accused persons could not be arraigned because they were not in court at the last adjourned date."



 
 Respond to this message   
Responses

  • 2006 Report's findings said to be absolutely appalling-calls on Pfizer to show records - admin on Aug 1
  •  


    Visit RxISK ORG from Data Based Medicine
    'the first free website (not sponsored by big pharma or advertising) for patients
    and their doctors to research, and more importantly, easily report drug side effects'.